Aligos Therapeutics (ALGS)
Develops liver- and viral-disease drug candidates, including a chronic hepatitis B program.
$6.01
vs last close+0.52 (+9.41%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 55.07% | 6.88M shares | |
|---|---|---|---|
| 31 holders · as of Jun 30, 2026 | |||
| Other | 44.93% | 5.61M shares | |
| remainder | |||
12.49M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (12.49M in the company's Sep 22, 2026 report, 6.19M elsewhere); stakes use the report.
This company has 3 share classes; every stake here is a share of the whole company.
13F, as of Jun 30, 2026
31 holders · 2.29M shares · 5 new positions · 12 increased · 7 reduced · 8 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 444.1K | 3.56% | 0 | Aug 14, 2026 |
| Alyeska Investment Group, L.P. | 412.0K | 3.30% | 0 | Aug 14, 2026 |
| Sio Capital Management, LLC | 327.2K | 2.62% | 0 | Aug 14, 2026 |
| Marshall Wace, LLP | 246.6K | 1.97% | −20.6K | Aug 13, 2026 |
| Woodline Partners LP | 177.4K | 1.42% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 175.5K | 1.41% | −2.7K | Aug 13, 2026 |
| Baker Bros. Advisors LP | 83.1K | 0.67% | 0 | Aug 14, 2026 |
| HHLR Advisors, Ltd. | 76.2K | 0.61% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 9.99% | 530.0K | 13G | May 15, 2025 |
| Adage Capital Management, L.P.incl. Robert Atchinson, Phillip Gross | 7.12% | 218.8K | 13G | Nov 12, 2024 |
| Lawrence M. Blatt | 5.60% | 316.2K | 13D | Jun 24, 2026 |
| Sio Capital Management, LLC | 5.46% | 335.9K | 13G | Feb 11, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.